Chi Chiu Mok
Tuen Mun Hospital · Tuen Mun Hospital, Hong Kong, China
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Chi Chiu Mok as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:48 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT06472050 · Romosozumab Versus Denosumab in Glucocorticoid-induced Osteoporosis: an Extended Observation of a Randomized Controlled Trial at 48 MonthsTuen Mun Hospital · completed · Osteoporosis, Glucocorticoids Toxicity · principal investigator
- N/ANCT05182203 · Safety and Retention Rate of the JAK and TNF Inhibitors in Rheumatoid Arthritis: a Real-life ExperienceTuen Mun Hospital · completed · Rheumatoid Arthritis, Drug Use · principal investigator
- Ph4NCT04748939 · Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCTTuen Mun Hospital · withdrawn · Herpes Zoster · principal investigator
- Ph4NCT04091243 · Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid UsersTuen Mun Hospital · completed · Glucocorticoid-induced Osteoporosis · principal investigator
- N/ANCT04089930 · Long-term Immunogenicity of a Live Herpes Zoster Vaccine in Systemic Lupus Erythematosus (SLE) PatientsTuen Mun Hospital · completed · Lupus Erythematosus · principal investigator
- Ph4NCT01465568 · Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced OsteoporosisTuen Mun Hospital · completed · Osteoporosis · principal investigator
- Ph4NCT00911521 · Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled StudyTuen Mun Hospital · completed · Systemic Lupus Erythematosus · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:48 UTC. The ranking covers the 200 most relevant of 30 PubMed records, and a shared surname and initials can bring in a namesake. All 30 on PubMed
- Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.N Engl J Med · 2020804 citationsRCR 40.9
- Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.Ann Rheum Dis · 2016164 citationsRCR 7.1
- Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis.Arthritis Care Res (Hoboken) · 2011146 citationsRCR 4.7
- Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study.Ann Rheum Dis · 2013140 citationsRCR 4.9
- Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study.Kidney Int · 2005105 citationsRCR 2.8
- Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine.Arthritis Rheum · 2002104 citationsRCR 3.0
- Rituximab for refractory polymyositis: an open-label prospective study.J Rheumatol · 200783 citationsRCR 2.6
- Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens.Am J Kidney Dis · 200176 citationsRCR 2.5
- Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis.Ann Rheum Dis · 202062 citationsRCR 3.5
- 61 citationsRCR 2.6